Results 201 to 210 of about 3,954,159 (357)

Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?

open access: hybrid
Calogera Claudia Spagnolo   +9 more
openalex   +1 more source

Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer

open access: yesMolecular Oncology, EarlyView.
COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann   +61 more
wiley   +1 more source

Corrigendum: Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

open access: yesFrontiers in Pharmacology, 2021
Yihui Zhou   +10 more
doaj   +1 more source

Polyamine inhibitors [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 1986
openaire   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Targeting the JAK/STAT pathway in atopic dermatitis. [PDF]

open access: yesFront Immunol
Cui L, Liu P, Wu K, Han X, Peng G.
europepmc   +1 more source

HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor

open access: hybrid, 1998
Julianna Lisziewicz   +4 more
openalex   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy